Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Beitsch

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2004
HER-2 gene amplification can be acquired as breast cancer progressesSongdong Meng, Debasish Tripathy, Sanjay Shete, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2011
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancerNeil Senzer, Minal Barve, Joseph Kuhn, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2004
HER-2 gene amplification can be acquired as breast cancer progressesSongdong Meng, Debasish Tripathy, Sanjay Shete, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2011
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancerNeil Senzer, Minal Barve, Joseph Kuhn, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Pageof 5